Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

Leukemia, Myeloid, Chronic-Phase Clinical Trial

— ACTIW  

Official title:

Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02767063
• Other study ID #: P13/12_ACTIW
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: July 2016
• Est. completion date: June 2023

Study information

• Verified date: August 2020
• Source: Versailles Hospital
• Contact: Laure MORISSET
• Phone: 003339239785
• Email: lmorisset[@]ch-versailles.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients will be randomized in phase II trials to continue on the same TKI versus one of the alternative treatment approaches. If a patient is not eligible for one of the treatments, he (she) will be randomized between the options for which he (she) is eligible.

The trial will start with current available treatment options (experimental arms). New available treatment options may be open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib.

For all options the treatment duration is for a minimum of 12 months and will be continued in the absence of adverse events following investigator decision. Each therapeutic option will be detailed in term of combination modalities, dose, dose adaptation, specific warnings, specific exclusion and inclusion criteria. The decision to introduce a new option will depend on the general pace of recruitment and on the assessment of the potential efficacy and safety of the new treatment, and will be implemented after scientific review by a protocol amendment.

Primary objective:

A. To select molecules in combination or sequentially with imatinib, nilotinib, dasatinib, bosutinib or ponatinib potentially able to produce a 25% increase in the Cumulative Incidence of MR4.5 as compare to control.

Secondary objectives:

A. To determine the safety of selected therapies

B. To determine the rate of MR4 by 12, 24, 36, 48 months in experimental and control arms

C. To determine the rates of MR4.5 by 24, 36, 48 months in experimental and control arms

D. To determine the rate of undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12, 24, 36, 48 months in experimental and control arms

E. To estimate treatment free remission (TFR) in patients eligible for discontinuation studies

F. To investigate the relationship between biological activity and the clinical efficacy of the selected therapies

G. To assess the effects of the treatments on the number and clonogenicity of CML stem cells and other biological markers of interest

H. To estimate duration of response, progression-free survival, event free survival and overall survival.

Description:

Patients will be randomised to continue on TKI (same daily dose) versus one of the alternative novel treatment approaches. If a patient is not eligible for one of the treatments, he can be randomised for the options for which he is eligible. All treatment options may be open at all times. Investigators must specify before randomization for which treatment option they want their patient be included and randomized.

Perspectives New treatment options will be introduced over time. The decision to introduce a new option will depend on the general pace of recruitment and the assessment of the potential efficacy and safety of the new treatment in this patient population, and will be implemented after scientific review by a protocol amendment.

The available treatment arms are:

1. TKI alone same daily dose (control arm)

2. TKI in combination with pioglitazone

3. TKI in combination with Avelumab (anti-PD-L1 antibody)

Planned treatment arms for the future may be :

1. TKI in combination with pegylated interferon

2. TKI in combination with arsenic trioxide

3. TKI in combination with Homoharringtonine

Protocol plan:

1. Control arm (Imatinib, nilotinib, dasatinib, bosutinib or ponatinib):

Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

2. Pioglitazone arm

• TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

• PIOGLITAZONE (Actos®):

30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.

• After 12 Months :

Continue TKI at the same daily dose and STOP pioglitazone.

3. AVELUMAB arm

• TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

• AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)

• After 12 Months :Continue TKI at the same daily dose.

4. Other experimental arm TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

• Arsenic trioxide : to be determined after amendment

• Pegylated Interferon : to be determined after amendment

• Homoharringtonine : to be determined after amendment

• Drug X

• Drug Y

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 2023
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Common Inclusion Criteria:

1. Patient aged 18y or more

2. Signed informed consent

3. Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL1 transcript positivity at diagnosis

4. Treatment with imatinib, nilotinib, dasatinib or bosutinib for more than 2 years overall

5. No switch between tyrosine kinase inhibitors within the last 3 months

6. No dose modification within the last 3 months

7. Complete cytogenetic response or BCR-ABL1IS = 1%

8. Detectable BCR-ABL1 with BCR-ABL1IS > 0.0032% (less than MR4.5)

9. ECOG grade 0 to 2

10. ASAT and ALAT = 2.5 N

11. Bilirubin in serum = 2.5 N

12. Men and Women of childbearing potential must be using an adequate method of contraception

These specific inclusion criteria will apply for the Avelumab arm in addition to the common criteria.

1. Hematologic:

1. Absolute neutrophil count (ANC) = 1.5 × 109/L,

2. Platelet count = 100 × 109/L,

3. Hemoglobin = 9 g/dL. (may have been transfused).

2. Hepatic:

a. Total bilirubin level = 1.5 × the upper limit of normal (ULN) range.

3. Renal: Estimated creatinine clearance = 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)

4. Pregnancy test: Negative serum or urine pregnancy test at screening for women of childbearing potential.

5. Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last Avelumab treatment administration if the risk of conception exists.

Common Exclusion Criteria:

1. Pregnant or lactating women,

2. Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment,

3. Prior history of hematopoietic stem cell transplantation (autologous or allogenic)

4. Cardiovascular disease:

• Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure.

• Myocardial infarction within the previous 6 months

• Symptomatic cardiac arrhythmia requiring treatment

5. Grade III or IV fluid retention

6. Known BCR-ABL kinase domain mutation

7. CML patient not in chronic phase at diagnosis

8. Individuals with an active malignancy

9. Known HIV-positivity

These specific exclusion criteria will apply for the pioglitazone arm in addition to the common criteria.

1. Known osteoporosis with curative therapy (prophylactic therapy is not an exclusion criteria)

2. Patient requiring anti-diabetic medication

These specific exclusion criteria will apply for the Avelumab arm in addition to the common criteria:

1. IMMUNOSUPRESSANTS: Current use of immunosuppressive medication, EXCEPT for the following:

1. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection);

2. Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent;

3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

2. AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.

3. ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation.

4. INFECTIONS: Active infection requiring systemic therapy.

5. HIV/AIDS: Known history of testing positive for HIV or known acquired immunodeficiency syndrome.

6. HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)

7. VACCINATION: Vaccination within 4 weeks of the first dose of Avelumab and while on trials is prohibited except for administration of inactivated vaccines

8. HYPERSENSITIIVTY TO STUDY DRUG: Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions tomonoclonal antibodies (NCI CTCAE v4.03 Grade = 3)

9. CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease:

cerebral vascular accident/stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia equiring medication.

10. OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade = 2, or other Grade = 2 not constituting a safety risk based on investigator's judgment are acceptable.

11. Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic-Phase

Intervention

Drug:
• Pioglitazone
PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.
• Avelumab
10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)

Locations

Country	Name	City	State
France	Martine GARDEMBAS	Angers
France	Pascale CONY.MAKHOUL	Annecy
France	Thorsten BRAUN	Bobigny
France	Etienne	Bordeaux
France	CHU Côte de Nacre	Caen
France	CHU Estaing	Clermont-Ferrand
France	CH Henri Mondor	Créteil
France	Rousselot	Le Chesnay
France	CHU Lille	Lille
France	CHU de LIMOGES	Limoges
France	Franck NICOLINI	Lyon
France	Institut P Calmette	Marseille
France	Viviane DUBRUILLE	Nantes
France	Hopital l'Archet	Nice
France	Eric JOURDAN	Nimes
France	Hôpital La Source	Orléans
France	Delphine REA _St louis	Paris
France	Simona LAPUSAN_St Antoine	Paris
France	Cayssials	Poitiers
France	CHU de Rennes - Pontchaillou	Rennes
France	Hôpital René Huguenin	Saint-Cloud
France	Institut Universitaire contre le Cancer	Toulouse
France	CHU Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Versailles Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative incidence of patients achieving a deep molecular response	The cumulative incidence of patients achieving a deep molecular response defined by MR4.5 or deeper (BCR-ABLIS = 0.0032 %) by 12 months	12 months
Secondary	Adverse events	Adverse events	12 Months
Secondary	The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms	The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms	24 months
Secondary	The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms	The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms	36 months
Secondary	The cumulative rate of patients achieving MR4.5 by 48 months in experimental and control arms	The cumulative rate of patients achieving MR4.5 by 48months in experimental and control arms	48 months
Secondary	The cumulative rate of patients achieving MR4 by 12months in experimental and control arms	The cumulative rate of patients achieving MR4 by 12,months in experimental and control arms	12 months
Secondary	The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms	The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms	24 months
Secondary	The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms	The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms	36 months
Secondary	The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms	The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms	48 months
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms	12 months
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24months in experimental and control arms	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24, months in experimental and control arms	24 months
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms	36 months
Secondary	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms	The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms	48 months
Secondary	The rate of patients in treatment free remission during follow-up	The rate of patients in treatment free remission during follow-up	48 months
Secondary	Quantification of CML- and normal-CFU in bone marrow by clonogenic assays and RTQ- PCR		12 months
Secondary	Survival	Survival	48 months
Secondary	duration of response	duration of response	48 months
Secondary	event free survival	event free survival	48 months
Secondary	progression free survival	progression free survival	48 months